XU-HENG CHIANGMONG-WEI LINJIN-SHING CHEN2021-10-082021-10-082020-031068-9265https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076889186&doi=10.1245%2fs10434-019-08147-4&partnerID=40&md5=f655d41819f5aa41ccb5094a09070a59https://scholars.lib.ntu.edu.tw/handle/123456789/584314en[SDGs]SDG3cancer surgery; cancer survival; clinical trial; disease free survival; human; Letter; lung adenocarcinoma; lung lobectomy; lung resection; lymph node dissection; mediastinum lymph node; non small cell lung cancer; overall survival; treatment indication; tumor volume; cancer staging; lung adenocarcinoma; lung resection; lung tumor; mortality; non small cell lung cancer; pathology; survival rate; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Survival Rateletter10.1245/s10434-019-08147-4318488162-s2.0-85076889186